The effect of atorvastatin on breast cancer biomarkers in high-risk women

Yongli Ji, Tiffany Rounds, Abigail Crocker, Betsy Sussman, Russell C. Hovey, Fonda Kingsley, Hyman B. Muss, Judy E. Garber, Marie E. Wood

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Statins have the potential to reduce breast cancer incidence and recurrence as shown in both epidemiologic and laboratory studies. The purpose of this study was to evaluate the effect of a lipophilic statin, atorvastatin, on breast cancer biomarkers of risk [mammographic density (MD) and insulin growth factor 1 (IGF-1)] in high-risk premenopausal women. Premenopausal women at increased risk for breast cancer received either 40 mg of atorvastatin or placebo for 1 year. Biomarker assessment was performed prior to initiation and at completion of study medication. MD was determined using both Breast Imaging Reporting and Data System and the visual analogue scale. Serum IGF-1 was determined by ELISA assay at the end of the study. Sixty-three women were enrolled between December 2005 and May 2010. Sixteen (25%) women withdrew. The mean age of participants was 43 (range, 35-50), 100% were white, and the average body mass index (BMI) was 26.4. The statin group demonstrated a significant decrease in cholesterol and low-density lipoprotein (LDL), suggesting compliance with study medication. After accounting for BMI, there was no difference in change in MD between groups. There was a significant increase in serum IGF-1 in the statin group. In this multi-institutional randomized prospective clinical trial of premenopausal women at increased risk for breast cancer, we did not see an effect of atorvastatin on MD. Further investigation of statins may be warranted; however, design of prior trials and potential mechanism of action of the agent need to be considered in the design of future trials. Cancer Prev Res; 9(5); 379-84.

Original languageEnglish (US)
Pages (from-to)379-384
Number of pages6
JournalCancer Prevention Research
Volume9
Issue number5
DOIs
StatePublished - May 1 2016

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Tumor Biomarkers
Breast Neoplasms
Intercellular Signaling Peptides and Proteins
Insulin
Body Mass Index
Serum
Visual Analog Scale
Information Systems
LDL Cholesterol
Action Potentials
Epidemiologic Studies
Breast
Randomized Controlled Trials
Biomarkers
Enzyme-Linked Immunosorbent Assay
Placebos
Atorvastatin Calcium
Recurrence
Breast Density

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ji, Y., Rounds, T., Crocker, A., Sussman, B., Hovey, R. C., Kingsley, F., ... Wood, M. E. (2016). The effect of atorvastatin on breast cancer biomarkers in high-risk women. Cancer Prevention Research, 9(5), 379-384. https://doi.org/10.1158/1940-6207.CAPR-15-0300

The effect of atorvastatin on breast cancer biomarkers in high-risk women. / Ji, Yongli; Rounds, Tiffany; Crocker, Abigail; Sussman, Betsy; Hovey, Russell C.; Kingsley, Fonda; Muss, Hyman B.; Garber, Judy E.; Wood, Marie E.

In: Cancer Prevention Research, Vol. 9, No. 5, 01.05.2016, p. 379-384.

Research output: Contribution to journalArticle

Ji, Y, Rounds, T, Crocker, A, Sussman, B, Hovey, RC, Kingsley, F, Muss, HB, Garber, JE & Wood, ME 2016, 'The effect of atorvastatin on breast cancer biomarkers in high-risk women', Cancer Prevention Research, vol. 9, no. 5, pp. 379-384. https://doi.org/10.1158/1940-6207.CAPR-15-0300
Ji, Yongli ; Rounds, Tiffany ; Crocker, Abigail ; Sussman, Betsy ; Hovey, Russell C. ; Kingsley, Fonda ; Muss, Hyman B. ; Garber, Judy E. ; Wood, Marie E. / The effect of atorvastatin on breast cancer biomarkers in high-risk women. In: Cancer Prevention Research. 2016 ; Vol. 9, No. 5. pp. 379-384.
@article{e4c60598ab894c90a461ce8a7976fce6,
title = "The effect of atorvastatin on breast cancer biomarkers in high-risk women",
abstract = "Statins have the potential to reduce breast cancer incidence and recurrence as shown in both epidemiologic and laboratory studies. The purpose of this study was to evaluate the effect of a lipophilic statin, atorvastatin, on breast cancer biomarkers of risk [mammographic density (MD) and insulin growth factor 1 (IGF-1)] in high-risk premenopausal women. Premenopausal women at increased risk for breast cancer received either 40 mg of atorvastatin or placebo for 1 year. Biomarker assessment was performed prior to initiation and at completion of study medication. MD was determined using both Breast Imaging Reporting and Data System and the visual analogue scale. Serum IGF-1 was determined by ELISA assay at the end of the study. Sixty-three women were enrolled between December 2005 and May 2010. Sixteen (25{\%}) women withdrew. The mean age of participants was 43 (range, 35-50), 100{\%} were white, and the average body mass index (BMI) was 26.4. The statin group demonstrated a significant decrease in cholesterol and low-density lipoprotein (LDL), suggesting compliance with study medication. After accounting for BMI, there was no difference in change in MD between groups. There was a significant increase in serum IGF-1 in the statin group. In this multi-institutional randomized prospective clinical trial of premenopausal women at increased risk for breast cancer, we did not see an effect of atorvastatin on MD. Further investigation of statins may be warranted; however, design of prior trials and potential mechanism of action of the agent need to be considered in the design of future trials. Cancer Prev Res; 9(5); 379-84.",
author = "Yongli Ji and Tiffany Rounds and Abigail Crocker and Betsy Sussman and Hovey, {Russell C.} and Fonda Kingsley and Muss, {Hyman B.} and Garber, {Judy E.} and Wood, {Marie E.}",
year = "2016",
month = "5",
day = "1",
doi = "10.1158/1940-6207.CAPR-15-0300",
language = "English (US)",
volume = "9",
pages = "379--384",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - The effect of atorvastatin on breast cancer biomarkers in high-risk women

AU - Ji, Yongli

AU - Rounds, Tiffany

AU - Crocker, Abigail

AU - Sussman, Betsy

AU - Hovey, Russell C.

AU - Kingsley, Fonda

AU - Muss, Hyman B.

AU - Garber, Judy E.

AU - Wood, Marie E.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Statins have the potential to reduce breast cancer incidence and recurrence as shown in both epidemiologic and laboratory studies. The purpose of this study was to evaluate the effect of a lipophilic statin, atorvastatin, on breast cancer biomarkers of risk [mammographic density (MD) and insulin growth factor 1 (IGF-1)] in high-risk premenopausal women. Premenopausal women at increased risk for breast cancer received either 40 mg of atorvastatin or placebo for 1 year. Biomarker assessment was performed prior to initiation and at completion of study medication. MD was determined using both Breast Imaging Reporting and Data System and the visual analogue scale. Serum IGF-1 was determined by ELISA assay at the end of the study. Sixty-three women were enrolled between December 2005 and May 2010. Sixteen (25%) women withdrew. The mean age of participants was 43 (range, 35-50), 100% were white, and the average body mass index (BMI) was 26.4. The statin group demonstrated a significant decrease in cholesterol and low-density lipoprotein (LDL), suggesting compliance with study medication. After accounting for BMI, there was no difference in change in MD between groups. There was a significant increase in serum IGF-1 in the statin group. In this multi-institutional randomized prospective clinical trial of premenopausal women at increased risk for breast cancer, we did not see an effect of atorvastatin on MD. Further investigation of statins may be warranted; however, design of prior trials and potential mechanism of action of the agent need to be considered in the design of future trials. Cancer Prev Res; 9(5); 379-84.

AB - Statins have the potential to reduce breast cancer incidence and recurrence as shown in both epidemiologic and laboratory studies. The purpose of this study was to evaluate the effect of a lipophilic statin, atorvastatin, on breast cancer biomarkers of risk [mammographic density (MD) and insulin growth factor 1 (IGF-1)] in high-risk premenopausal women. Premenopausal women at increased risk for breast cancer received either 40 mg of atorvastatin or placebo for 1 year. Biomarker assessment was performed prior to initiation and at completion of study medication. MD was determined using both Breast Imaging Reporting and Data System and the visual analogue scale. Serum IGF-1 was determined by ELISA assay at the end of the study. Sixty-three women were enrolled between December 2005 and May 2010. Sixteen (25%) women withdrew. The mean age of participants was 43 (range, 35-50), 100% were white, and the average body mass index (BMI) was 26.4. The statin group demonstrated a significant decrease in cholesterol and low-density lipoprotein (LDL), suggesting compliance with study medication. After accounting for BMI, there was no difference in change in MD between groups. There was a significant increase in serum IGF-1 in the statin group. In this multi-institutional randomized prospective clinical trial of premenopausal women at increased risk for breast cancer, we did not see an effect of atorvastatin on MD. Further investigation of statins may be warranted; however, design of prior trials and potential mechanism of action of the agent need to be considered in the design of future trials. Cancer Prev Res; 9(5); 379-84.

UR - http://www.scopus.com/inward/record.url?scp=84969973364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969973364&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-15-0300

DO - 10.1158/1940-6207.CAPR-15-0300

M3 - Article

C2 - 26908565

AN - SCOPUS:84969973364

VL - 9

SP - 379

EP - 384

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 5

ER -